1425486-32-3

Upstream product

• 1425486-31-2 N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)pivalamide 
• 1425486-30-1 N-(2,4,5-trifluoro-3-(hydroxy(3-morpholinoquinoxalin-6-yl)methyl)phenyl)pivalamide 
• 916811-89-7 3-morpholinoquinoxaline-6-carbaldehyde 
• 916811-87-5 4-(7-bromoquinoxalin-2-yl)morpholine 
• 89891-65-6 7-bromo-2-chloroquinoxaline 
• 82031-32-1 7-bromo-1H-quinoxalin-2-one 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 1425486-33-4 N-(propylsulfonyl)-N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide 
• 1425485-87-5 C₂₂H₂₁F₃N₄O₄S 
• 1427633-05-3 N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)-3-(trifluoromethyl)benzamide 
• 1427632-35-6 1-(3-fluorophenyl)-3-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)urea 

Relevant academic research and scientific papers

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions c

Certain Chemical Entities, Compositions, and Methods

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.